Glaukos Co. (NYSE:GKOS) Insider Tomas Navratil Sells 3,416 Shares

Glaukos Co. (NYSE:GKOS) insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Glaukos Stock Up 5.5 %

Shares of NYSE:GKOS traded up $8.34 on Wednesday, hitting $161.30. 1,149,144 shares of the company’s stock were exchanged, compared to its average volume of 553,808. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 1-year low of $83.90 and a 1-year high of $163.71. The company has a market capitalization of $8.89 billion, a PE ratio of -53.41 and a beta of 1.04. The firm’s 50-day moving average is $151.95 and its 200 day moving average is $138.62.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently added to or reduced their stakes in the stock. WCM Investment Management LLC boosted its holdings in shares of Glaukos by 45.7% in the 3rd quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier’s stock valued at $12,721,000 after buying an additional 31,084 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Glaukos by 186.9% in the third quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock valued at $1,788,000 after acquiring an additional 8,942 shares in the last quarter. First Turn Management LLC purchased a new position in shares of Glaukos during the third quarter worth about $12,520,000. Harbor Capital Advisors Inc. purchased a new position in shares of Glaukos during the fourth quarter worth about $3,679,000. Finally, Victory Capital Management Inc. increased its position in shares of Glaukos by 421.8% during the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier’s stock worth $10,320,000 after purchasing an additional 64,031 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GKOS. Mizuho upgraded Glaukos from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $140.00 to $200.00 in a research report on Wednesday. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus increased their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. Piper Sandler reiterated an “overweight” rating and set a $180.00 price target (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Finally, Morgan Stanley lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and an average target price of $159.42.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.